Cardinal Health Inc. (CAH - Free Report) reported fourth-quarter fiscal 2017 adjusted earnings of $1.31 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 14.9% on a year-over-year basis.
Revenues increased 5% on a year-over-year basis to almost $33 billion, beating the Zacks Consensus Estimate of $32.8 billion.
Pharmaceutical Segment: Pharmaceutical revenues rose 5% to $29.6 billion on a year-over-year basis. The segment witnessed strong growth in the Specialty business and also gained a huge number of Pharmaceutical Distribution customers.
However, generic pharmaceutical pricing and the company's recent investments in its Pharmaceutical IT platform led to a 7% drop in segmental profits. However, solid performance by the Red Oak Sourcing platform has partially offset the negative effect.
Medical Segment: Revenues at the segment increased 9% to $3.4 billion primarily on higher contributions from new and existing customers.
Medical segment profits increased 13% to $138 million, courtesy of higher contributions from new and existing customers and solid performance by the post-acute segment. However, unfavorable performances by Cardinal Health Branded products (including Cordis) partially offset sales at the segment.
Other Details: Distribution, selling, general and administrative (SG&A) expenses increased 3% on a year-over-year basis to $377 million in the reported quarter. Cash and equivalents were $6879 million as of Jun 30, 2017.
For fiscal 2017, Cardinal Health registered adjusted earnings of $5.40 per share, up 3% on a year-over-year basis. Revenues increased 7% on a year-over-year basis to a record $130 billion.
Delving deeper into the segmental revenue details, Pharmaceutical segment (89.6% of net revenues) increased 7% to $116.5 billion in fiscal 2017. Medical segment (10.4% of net revenues) revenues soared 95% on a year-over-year basis to $13.5 billion.
The company issued fiscal 2018 guidance for adjusted earnings per share from continuing operations of $4.85–$5.10. Furthermore, Cardinal Health is expected to register fiscal 2019 adjusted earnings per share of at least $5.60.
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corporation (EW - Free Report) , Abiomed Inc. (ABMD - Free Report) and Fresenius Medical Care Corporation (FMS - Free Report) .
Notably, Fresenius Medical Care and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Abiomed has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Fresenius Medical Care represents a return of 2.5% over the last one year. The company delivered a solid earnings surprise of 20.5% in the last reported quarter.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. Notably, the stock has a one-year return of 1.5%.
Abiomed yielded a strong return of 23.4% over the last one year. The stock has a long-term expected earnings growth rate of 30.5%.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>